{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:57:58Z","timestamp":1787925478068,"version":"build-2784847793"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T00:00:00Z","timestamp":1314748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>B\u2010cell lymphoma, Unclassifiable with features intermediate between diffuse large B\u2010cell lymphoma (DLBCL) and Burkitt lymphoma, for convenience referred to here as unclassifiable B\u2010cell lymphoma, is a category in the 2008 World Health Organization system used for a group of histologically aggressive neoplasms that are difficult to classify definitively. Currently, there is no established standard therapy for these neoplasms.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors assessed <jats:italic>MYC<\/jats:italic> status and correlated it with treatment response and outcome in a group of 52 patients with unclassifiable B\u2010cell lymphoma treated with either a standard DLBCL regimen (R\u2010CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone\u2010related therapy]) or more intensive regimens, such as R\u2010hyper\u2010CVAD (rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high\u2010dose methotrexate and cytarabine). The regimens were selected by the treating clinicians based on the overall clinical and pathological findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Thirty (58%) unclassifiable B\u2010cell lymphomas had <jats:italic>MYC<\/jats:italic> abnormalities (<jats:italic>MYC<\/jats:italic><jats:sup>+<\/jats:sup>) including 27 with rearrangement, 2 with amplification, and 1 with both. The <jats:italic>MYC<\/jats:italic><jats:sup>+<\/jats:sup> and <jats:italic>MYC<\/jats:italic><jats:sup>\u2212<\/jats:sup> groups were similar in their age distribution and International Prognostic Index scores. Progression\u2010free survival of patients with <jats:italic>MYC<\/jats:italic><jats:sup>+<\/jats:sup> unclassifiable B\u2010cell lymphoma treated initially with R\u2010CHOP was significantly worse than patients treated with R\u2010hyper\u2010CVAD (<jats:italic>P<\/jats:italic> = .0358). In contrast, for the <jats:italic>MYC<\/jats:italic><jats:sup>\u2212<\/jats:sup> unclassifiable B\u2010cell lymphoma group, some patients responded to R\u2010CHOP, and others were refractory to R\u2010hyper\u2010CVAD.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p><jats:italic>MYC<\/jats:italic> aberrations are common in unclassifiable B\u2010cell lymphoma. The presence of <jats:italic>MYC<\/jats:italic> aberrations identifies a patient subset that requires more aggressive therapy than R\u2010CHOP. In contrast, <jats:italic>MYC<\/jats:italic><jats:sup>\u2212<\/jats:sup> unclassifiable B\u2010cell lymphoma patients responded variably to either R\u2010CHOP or aggressive therapy, and the latter showed no survival advantage. Cancer 2011;. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26433","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T02:38:49Z","timestamp":1314844729000},"page":"1566-1573","source":"Crossref","is-referenced-by-count":64,"title":["Prognostic value of <i>MYC<\/i> rearrangement in cases of B\u2010cell lymphoma, unclassifiable, with features intermediate between diffuse large B\u2010cell lymphoma and Burkitt lymphoma"],"prefix":"10.1002","volume":"118","author":[{"given":"Pei","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Dickason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Routbort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xumei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.10.027"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055351"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055759"},{"key":"e_1_2_6_5_2","first-page":"265","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Kluin PM","year":"2008"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.281"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP15YFULCZHZVH"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1309\/FDGWB5C2MYRYXH2E"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.92"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2006.07.014"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-220095"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.230"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3947"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2009.065227"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.01035.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-297879"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800500"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1558"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11305"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212191"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11263"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.005355"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26433","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:15:33Z","timestamp":1760285733000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,31]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,3,15]]}},"alternative-id":["10.1002\/cncr.26433"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26433","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,31]]}}}